Bristol Myers Squibb (BMY) exceeded expectations in the fourth quarter, driven by robust demand for its cancer immunotherapy treatment, Opdivo, and the blood thinner Eliquis. Adjusted earnings per share reached $1.26, surpassing analysts' predictions, although down from the previous year. Revenue also rose to $12.50 billion, exceeding the anticipated $12.27 billion, showcasing the company's strong performance.

Sales of Opdivo saw an 8.6% increase, reaching $2.69 billion. Eliquis also performed well, with revenues increasing by 8.1% to $3.45 billion. This positive performance reflects the ongoing success of these key drugs in the market. The pharmaceutical giant continues to benefit from its focus on oncology and cardiovascular treatments, key growth areas.

The results highlight Bristol Myers Squibb's ability to navigate the competitive pharmaceutical market, especially in the growing cancer treatment sector. The company's performance is closely watched by investors. Further developments in the company’s product pipeline and the continued success of its key drugs will be important factors to watch moving forward.